The interaction of vasopressin and corticosteroids in septic shock: A pilot randomized controlled trial

Critical Care Medicine

Volumn 42, Issue 6, 2014, Pages 1325-1333

  Gordon, Anthony C ^a,b   Mason, Alexina J ^c   Perkins, Gavin D ^d,e   Stotz, Martin ^b   Terblanche, Marius ^f,g   Ashby, Deborah ^c   Brett, Stephen J ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adrenal cortex hormones; drug interactions; intensive care; multiple organ failure; sepsis; vasopressins

Indexed keywords

CORTICOSTEROID; HYDROCORTISONE SODIUM PHOSPHATE; LACTIC ACID; PLACEBO; TROPONIN; VASOPRESSIN;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CHRONOTHERAPY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTENSION; INFUSION RATE; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPEN STUDY; PERIPHERAL VASCULAR DISEASE; PILOT STUDY; PRESSOR RESPONSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VASOPRESSIN BLOOD LEVEL;

AGED; ANTI-INFLAMMATORY AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; ORGAN DYSFUNCTION SCORES; PILOT PROJECTS; PROSPECTIVE STUDIES; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 84901497746     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000212     Document Type: Article

References (39)

1. Torgersen C, Dü nser MW, Schmittinger CA, et al: Current approach to the haemodynamic management of septic shock patients in European intensive care units: A cross-sectional, self-reported questionnaire-based survey. Eur J Anaesthesiol 2011; 2 8:284-290
2. Landry DW, Levin HR, Gallant EM, et al: Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997; 25:1279-1282
3. Gordon AC, Wang N, Walley KR, et al: The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest 2012; 142:593-605
4. Patel BM, Chittock DR, Russell JA, et al: Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96:576-582
5. Lauzier F, Lé vy B, Lamarre P, et al: Vasopressin or norepinephrine in early hyperdynamic septic shock: A randomized clinical trial. Intensive Care Med 2006; 32:1782-1789
6. Russell JA, Walley KR, Singer J, et al; VASST Investigators: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877-887
7. Gordon AC, Russell JA, Walley KR, et al: The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 2010; 36:83-91
8. Russell JA, Walley KR, Gordon AC, et al; for the Vasopressin and Septic Shock Trial Investigators: Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009; 37:811-818
9. Torgersen C, Dü nser MW, Wenzel V, et al: Comparing two different arginine vasopressin doses in advanced vasodilatory shock: A randomized, contr olled, open-label trial. Intensive Care Med 2010; 36:57-65
10. Torgersen C, Luckner G, Schröder DC, et al: Concomitant arginine-vasopressin and hydrocortisone therapy in severe septic shock: Ass ociation with mortality. Intensive Care Med 2011; 37:1432-1437
11. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guide lines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
12. Sprung CL, Annane D, Keh D, et al; CORTICUS Study Group: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124
13. Dellinger RP, Levy MM, Carlet JM, et al; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American Colle ge of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; Internatio n al Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Car e Medicine: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
14. Penney MD, Hampton D, Oleesky DA, et al: Radioimmunoassays of arginine vasopressin and atrial natriuretic peptide: Application of a common protocol for plasma extraction using Sep-Pak C18 cartridges. Ann Clin Bioch em 1992; 29:652-658
15. Vincent JL, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Se psis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-710
16. Mehta RL, Kellum JA, Shah SV, et al; Acute Kidney Injury Network: Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31
17. Bellomo R, Ronco C, Kellum JA, et al; Acute Dialysis Quality Initiative Workgroup: Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-R212
18. R Core Team: R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2012
19. Malay MB, Ashton RC Jr, Landry DW, et al: Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999; 47:699-703
20. Dü nser MW, Mayr AJ, Ulmer H, et al: Arginine vasopressin in advanced vasodilatory shock: A prospective, randomized, controlled study. Circulation 2003; 107:2313-2319
21. Sun Q, Dimopoulos G, Nguyen DN, et al: Low-dose vasopressin in the treatment of septic shock in sheep. Am J Respir Crit Care Med 2003; 168:481-486
22. Choong K, Bohn D, Fraser DD, et al; Canadian Critical Care Trials Group: Vasopressin in pediatric vasodilatory shock: A multicenter randomized controlled trial. Am J Resp ir Crit Care Med 2009; 180:632-639
23. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: Internationa l guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637
24. Dü nser MW, Ruokonen E, Pettilä V, et al: Association of arterial blood pressure and vasopressor load with septic shock mortality: A post hoc analysis of a multicenter trial. Crit Care 2009; 13:R181
25. Ranieri VM, Thompson BT, Barie PS, et al; PROWESS-SHOCK Study Group: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055-2064
26. Aguilera G, Rabadan-Diehl C: Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: Implications for stress adaptation. Regul Pept 2000; 96:23-29
27. Brooks VL, Blakemore LJ: Vasopressin: A regulator of adrenal glucocorticoid production Am J Physiol 1989; 256:E566-E572
28. Levi J, Massry SG, Kleeman CR: The requirement of cortisol for the inhibitory effect of norepinephrine on the antidiuretic action of vasopressin. Proc Soc Exp Biol Med 1973; 142:687-690
29. Pietranera L, Saravia F, Roig P, et al: Mineralocorticoid treatment upregulates the hypothalamic vasopressinergic system of spontaneously hypertensive rats. Neuroendocrinology 2004; 80:100-110
30. Lauand F, Ruginsk SG, Rodrigues HL, et al: Glucocorticoid modulation of atrial natriuretic peptide, oxytocin, vasopressin and Fos expression in response to osmotic, angiotensinergic and cholinergic stimulation. Neuroscien ce 2007; 147:247-257
31. Streeten DH, Souma M, Ross GS, et al: Action of cortisol introduced into the supraoptic nucleus, on vasopressin release and antidiuresis during hypertonic saline infusion in c onscious rhesus monkeys. Acta Endocrinol (Copenh) 1981; 98:195-204
32. Kim JK, Summer SN, Wood WM, et al: Role of glucocorticoid hormones in arginine vasopressin gene regulation. Biochem Biophys Res Commun 2001; 289:1252-1256
33. Bucher M, Hobbhahn J, Taeger K, et al: Cytokine-mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats. Am J Physiol Regul Integr Comp Physiol 2002; 282:R979-R984
34. Ertmer C, Bone HG, Morelli A, et al: Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia. Shock 2007; 27:281-288
35. Moreno R, Sprung CL, Annane D, et al: Time course of organ failure in patients with septic shock treated with hydrocortisone: Results of the Corticus study. Intensive Care Med 2011; 37:1765-1772
36. Boonen E, Vervenne H, Meersseman P, et al: Reduced cortisol metabolism during critical illness. N Engl J Med 2013; 368:1477-1488
37. Rehberg S, Enkhbaa tar P, Rehberg J, et al: Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor. Crit Care Med 2012; 40:1957 -1960
38. De Backer D, Biston P, Devriendt J, et al; SOAP II Investigators: Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362:779-789
39. Mehta S,Granton J,Gordon AC,et al., for the Vasopressin and Septic Shock Trial (VASST) Investigators: Cardiac ischemia in patients with septic shock randomized to vasopressin or norepinephrine, Crit Care,2013,17, R117